Tuberculosis Clinical Trial
Official title:
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity and Efficacy of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Healthcare Workers
Verified date | May 2019 |
Source | Quratis Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the experimental tuberculosis (TB) vaccine called ID93+GLA-SE. The safety, immunogenicity, and efficacy of ID93+GLA-SE will be compared to placebo, after three intramuscular (IM) injections one month apart in healthy healthcare workers. The healthcare workers will all have had the childhood TB vaccine called BCG, and all of them must have a negative result for a blood test for exposure to the bacteria that cause TB (QuantiFERON-TB Gold Plus, or "QFT"). Study participants will be followed for 12 months after the last injection for safety reasons. Blood will be drawn for laboratory tests for safety, immunogenicity, and efficacy tests. Efficacy will be evaluated by further QFT testing. The study hypothesis is that the vaccine is safe, immunogenic, and effective in this study population.
Status | Active, not recruiting |
Enrollment | 107 |
Est. completion date | June 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 64 Years |
Eligibility |
Inclusion Criteria: 1. Male or female who is =19 and <65 years of age. 2. Healthcare workers who are QuantiFERON®-TB Gold Plus negative (not latently infected with Mtb) at screening. 3. Able to comply with the scheduled visits, and are expected to continue working in the current medical institution and be available for a continuous follow-up by the investigator via provided contact information. 4. Only for female subjects of childbearing potential: - Must be HCG-negative from serum or urine pregnancy test, at screening; - Agreed to use one of the following acceptable birth control methods to avoid pregnancy until the end of study (Visit 9): hormonal contraceptives, intrauterine device (IUD) or intrauterine system (IUS), tubal ligation, or combination of barrier methods (combined use of barrier methods such as male condoms, female condoms, cervical cap, diaphragm, sponge, or implant). 5. History of BCG vaccination that is confirmed through medical examination (i.e., asking a subject about his/her condition) or presence of a scar. 6. Body mass index (BMI) =19 and =33 (kg/m^2) at screening 7. Subjects who understand the study procedures, and voluntarily decide to participate in the study and sign the informed consent form.. Exclusion Criteria: 1. History of positive tuberculin skin test or positive QuantiFERON®-TB results. 2. History of severe chronic disease that may compromise the safety of the subject during the study (e.g., impairment of pulmonary function from tuberculosis infection or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or uncontrolled epilepsy). 3. Body temperature = 38? at the time of randomization or within 24 hours before randomization, from acute fever, acute respiratory diseases, or active infection. 4. Malignant tumors or a history of malignant tumors. 5. Plans to have surgery during the study period. 6. Impaired immune functions including autoimmune disease or immunodeficiency disease. 7. History of Guillain-Barre syndrome. 8. Subjects with a history of anaphylaxis or severe allergic reaction to vaccines, eggs, or other allergens. 9. Subjects living with a household member who has active TB or infectious TB. 10. Clinically significant abnormal laboratory values for any of the following tests conducted in the study center, prior to randomization: - Hemoglobin, hematocrit, absolute neutrophil count, absolute lymphocyte count, or platelet count: < LLN (lower limit of normal) - White blood cell count: >ULN (upper limit of normal) or <LLN (lower limit of normal) (i.e., must be within normal limits) - ALT, AST, total bilirubin, alkaline phosphatase, creatinine, or blood urea nitrogen (BUN): >ULN (upper limit of normal) 11. Received an immunosuppressant, immunity-modifying drug, or other treatment that may affect the immune system including cytotoxic anti-cancer agents or radiotherapy, within 3 months before the randomization. 12. Use of systemic steroids (equivalent to daily prednisone = 15mg/day for more than 14 days), inhaled or intranasal steroids, within 3 months before randomization; however, use of topical corticosteroids are acceptable, regardless of dose. 13. Use of immunoglobulin or blood products within 3 months before randomization or plans to use them during the study period. 14. Human Immunodeficiency Virus (HIV) positive at screening. 15. Subjects with chronic hepatitis (e.g., hepatitis B core antibody or hepatitis C antibody positive) at screening. 16. Unable to discontinue current chronic drug therapy such as thyroxin, insulin, or other medications with hepatotoxicity or myelotoxicity; however, estrogen and progesterone replacement therapy or contraceptives, and topical medications are acceptable. 17. Pregnant or lactating. 18. Received other vaccines within 4 weeks before screening or plans to receive them from the day of screening to 4 weeks after the last vaccination with the Investigational Product or within 4 weeks before the End Visit. 19. Received other investigational drugs within 4 weeks before screening. 20. Subjects deemed ineligible by investigator based on other reasons. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Ajou University Hospital | Gyeonggi-do | |
Korea, Republic of | Chung-Ang University Hospital | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul |
Lead Sponsor | Collaborator |
---|---|
Quratis Inc. | IDRI |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events | Solicited (local and systemic reactogenicity), unsolicited (all other adverse events, including laboratory assessments and vital signs), serious AEs and AEs of special interest. | Solicited AEs for 7 days following each injection, unsolicited AEs for 28 days after each injection, SAEs and AESIs for 12 months after the last injection. | |
Secondary | Humoral and cellular immunogenicity assays | Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at specified timepoints | Days 0, 28, 56, 84, and 12 months after last injection. | |
Secondary | Efficacy at prevention of latent Mtb infection (QFT conversion) | Positive response rate for latent tuberculosis infection from QuantiFERON®-TB Gold Plus assay. | 3 months and 14 months after the first injection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |